Summary
EXK Chart
Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up
EXAS posts Q4 revenue beat as Screening and Precision Oncology grow, margins expand, shares tick up and Abbott merger plans progress.
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of breakeven. This compares to a loss of $0.06 per share a year ago.
Exact Sciences Corp (EXK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Exact Sciences Corp ever had a stock split?
Exact Sciences Corp Profile
| Professional Services Industry | Industrials Sector | Kevin T. Conroy CEO | XBER Exchange | US30063P1057 ISIN |
| US Country | 6,900 Employees | - Last Dividend | - Last Split | 1 Feb 2001 IPO Date |
Overview
Exact Sciences Corporation is a prominent entity in the realm of healthcare, specifically focusing on the development and provision of cancer screening and diagnostic tests both within the United States and on a global scale. The company has carved out a niche for itself by offering innovative, non-invasive products that play a crucial role in early cancer detection and management. Established in 1995 and having its headquarters nestled in Madison, Wisconsin, Exact Sciences Corporation stands out for its commitment to revolutionizing cancer diagnostics through groundbreaking research and strategic partnerships, including those with the MAYO Foundation for Medical Education and Research, and Johns Hopkins University.
Products and Services
Exact Sciences Corporation offers a diverse portfolio of diagnostic tests and services aimed at cancer screening and diagnosis:
- Cologuard: A leading non-invasive, stool-based DNA screening test designed to identify DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. This test enables early detection which is crucial for effective treatment and management.
- Oncotype DX Breast Recurrence Score Test: A genomic test that helps in predicting the likelihood of breast cancer recurrence. It provides personalized information that assists in deciding on the necessity of chemotherapy in early-stage breast cancer patients.
- Oncotype DX Breast DCIS Score Test: Specifically designed for patients diagnosed with ductal carcinoma in situ (DCIS), this test helps predict the risk of recurrence and can guide decisions regarding the treatment plan.
- Oncotype DX Colon Recurrence Score Test: This test offers insights into the likelihood of colon cancer recurrence, assisting healthcare professionals in tailoring personalized treatment plans for patients.
- OncoExTra Test: Designed for patients dealing with advanced, metastatic, refractory, relapsed, or recurrent cancer, the OncoExTra Test offers comprehensive tumor profiling, facilitating the selection of targeted treatments based on the genomic characteristics of the tumor.
- Covid-19 testing services: In response to the global Covid-19 pandemic, Exact Sciences expanded its diagnostic portfolio to include testing services for the detection of Covid-19, showcasing its adaptability and commitment to addressing emergent health challenges.
Furthermore, Exact Sciences is dedicated to continuous innovation, as evidenced by its pipeline products that focus on enhancing the Cologuard test's performance and developing new blood and other fluid-based tests for cancer detection, underscoring its commitment to advancing cancer diagnosis and treatment.
